Release Date: June 5, 2013
BUFFALO, N.Y. and CARLSBAD, Calif. — Empire
Genomics, Life Technologies Corporation (NASDAQ: LIFE) and the
University at Buffalo will embark on a new partnership to develop
world-class gene sequencing facilities for genetics-based clinical
research on the Buffalo Niagara Medical Campus.
The collaboration capitalizes on each organization’s
strengths to help establish a new standard for genomic research in
Western New York and continue to grow the life sciences sector of
the region’s economy.
Life Technologies, a global provider of biotechnology products
and services, will provide state-of-the-art genome sequencing
equipment enabling UB and Empire Genomics to establish their
initial set up of Clinical Laboratory Improvement Amendments
(CLIA)-certified sequencing facilities on the Buffalo Niagara
The advanced sequencing technology available from Life
Technologies, combined with the expertise of UB researchers and the
Empire Genomics team, will help clinical researchers develop new
diagnostic tests that, in the future, could enable physicians to
prescribe treatments tailored to each individual based on genetic
“We are very pleased that after carefully looking at all
of the alternatives, the University at Buffalo and Empire Genetics
decided that Ion semiconductor sequencing was the best platform to
help them reach their goal of advancing genetics-based clinical
research, and ultimately driving growth in the life sciences
industry in Western New York,” said Mark Stevenson, president
and chief operating officer at Life Technologies.
Achieving CLIA certification will enhance and expand the
services Empire Genomics and UB provide to clients across the
globe, and holds the promise of spawning new diagnostic tests for a
number of diseases or conditions. The results will eventually lead
to new tools to deliver better health care while growing new jobs
in Western New York.
“This collaboration is a great example of the impact that
can be made when industry and academic partners work together
toward shared goals,” said Marnie LaVigne, PhD, associate
vice president for economic development at UB. “We look
forward to continuing to partner with Life Technologies and Empire
Genomics on these efforts to support the advancement of
genetics-based clinical research and the life sciences as key
economic drivers in our region.”
The CLIA-certified laboratories will be set up at UB’s New
York State Center of Excellence in Bioinformatics and Life Sciences
and at the downtown Buffalo headquarters of Empire Genomics, a
provider of genetics-based research and testing services.
“Genetics-based diagnostics will play a major role in
developing personalized medicine, and that in turn will create new
job opportunities in Western New York,” said Norma J. Nowak,
PhD, founder and chief scientific officer at Empire Genomics and
director of science and technology at UB’s New York State
Center of Excellence in Bioinformatics and Life Sciences.
“Leveraging our combined strengths will ensure that we remain
at the forefront of technological and research capabilities while
making greater long-term contributions to the public
About Empire Genomics, LLC
Empire Genomics delivers the most advanced genomic tools to facilitate the scientific community in its research and diagnostic challenges. Through many years of experience in the area of genomics and working with diverse sample types, Empire Genomics is able to provide continuous innovation for research and diagnostic applications in areas of oncology, biomarkers, drug discovery, constitutional disorders, developmental disorders and autism, among many others.
About the NYS Center of Excellence in Bioinformatics and Life
Sciences at UB
The mission of the University at Buffalo’s New York State Center of Excellence in Bioinformatics and Life Sciences is to foster economic development by connecting university resources with life sciences and high-tech industry through funding, research and development support, programming and education, with the goal of helping companies find business solutions, accelerate new ideas and grow. This technology-based economic development mission is complemented by the center’s efforts to support the advancement of new discoveries in science that seek better ways of preventing and managing disease and improving lives. Learn more at: www.bioinformatics.buffalo.edu.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum — scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012. Visit us at our website: http://www.lifetechnologies.com.
Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
All products referenced are for Research Use Only and not
intended for use in diagnostic procedures, unless otherwise